Leonidas Apostolidis

Dr. Leonidas Apostolidis

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
GHGeorg Martin Haag
Georg Martin Haag
CSChristoph Springfeld
Christoph Springfeld
BGBarbara Grün
Barbara Grün
LALeonidas Apostolidis
Leonidas Apostolidis
SZStefanie Zschäbitz
Stefanie Zschäbitz
DJDirk Jaeger
Dirk Jaeger

5 June 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KMKatja Mehlis
Katja Mehlis
JWJulian Witte
Julian Witte
BSBastian Surmann
Bastian Surmann
MKMatthias Kudlich
Matthias Kudlich
LALeonidas Apostolidis
Leonidas Apostolidis
EWEva C. Winkler
Eva C. Winkler
Background: Financial toxicity of cancer has so far been discussed primarily in the US health care system and is associated with higher morbidity and mortality. In European health care systems, the socio-economic impact of cancer is poorly understood. This study investigates the financial burden and patient-reported outcomes of neuroendocrine (NET) or colorectal (CRC) cancer patients at a German Comprehensive Cancer Center. Methods: This prospective cross-sectional study surveyed 247 advanced stage patients (n = 122 NET/n = 125 CRC) at the National Center for Tumor Diseases, in Germany about cancer-related out-of-pocket costs, income loss, distress, and quality of life. Multiple linear regression analysis was performed to demonstrate the effects of economic deterioration on patients’ quality of life and distress. Results: 81% (n = 199) of the patients reported out-of-pocket costs, and 37% (n = 92) income loss as a consequence of their disease. While monthly out-of-pocket costs did not exceed 200€ in 77% of affected patients, 24% of those with income losses reported losing more than 1.200€ per month. High financial loss relative to income was significantly associated with patients’ reporting a worse quality of life (p < .05) and more distress (p < .05). Conclusions: Financial toxicity in third-party payer health care systems like Germany is caused rather by income loss than by co-payments. Distress and reduced quality of life due to financial problems seem to amplify the burden that already results from a cancer diagnosis and treatment. If confirmed at a broader scale, there is a need for targeted support measures at the individual and system level.

16 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LALeonidas Apostolidis
Leonidas Apostolidis
ABArianna Dal Buono
Arianna Dal Buono
Elettra MerolaElettra Merola
Elettra Merola
HJHenning Jann
Henning Jann
DJDirk Jäger
Dirk Jäger
MPMarianne Ellen Pavel
Marianne Ellen Pavel
Well-differentiated grade 3 neuroendocrine tumors (NET G3) have been distinguished from poorly differentiated neuroendocrine carcinomas (NEC) in the most current WHO classifications. Commonly applied first-line chemotherapy protocols with cisplatin or carboplatin in combination with etoposide (PE) are less effective in NET G3 than NEC. Suggested alternative treatment protocols have not been studied in first-line therapy of NET G3 so far. We performed a retrospective analysis of patients with NET G3 in the databases of 3 German cancer centers. Out of 142 patients, 136 patients received palliative first-line therapy: overall response rate (ORR) was 35.1% for PE (n = 37), 56.4% for FOLFOX (n = 39), 27.3% for temozolomide/capecitabine (TEM/CAP) (n = 22), 45.0% for streptozotocin/5-fluorouracil (STZ/5-FU) (n = 20), and 16.7% for other (n = 18). Median progression-free survival (PFS) for PE was 6.9 months. Compared to PE, PFS in the other treatment groups was 6.9 months for FOLFOX (p = 0.333), 12.0 months for TEM/CAP (p = 0.093), 4.8 months for STZ/5-FU (p = 0.919), and 14.1 months for other (p = 0.014). In a univariate setting, all non-PE patients combined showed a significantly prolonged PFS vs. PE (9.0 months; p = 0.049) which could not be confirmed in a multivariate analysis. In conclusion, NET G3 with FOLFOX showed the highest ORR, and with TEM/CAP showed the longest PFS. Further prospective evaluation of the optimal therapeutic strategy for this tumor entity is needed.

29 November 2018 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
GHGeorg Martin Haag
Georg Martin Haag
ECElena Czink
Elena Czink
AAAysel Ahadova
Aysel Ahadova
Thomas SchmidtThomas Schmidt
Thomas Schmidt
LSLeila Sisic
Leila Sisic
MKMatthias Kloor
Matthias Kloor

1 January 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
LALeonidas Apostolidis
Leonidas Apostolidis
CNCathleen Nientiedt
Cathleen Nientiedt
EWEva Caroline Winkler
Eva Caroline Winkler
ABAnne Katrin Berger
Anne Katrin Berger
CKClemens Kratochwil
Clemens Kratochwil
CGCarsten Grüllich
Carsten Grüllich
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate

24 August 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LALeonidas Apostolidis
Leonidas Apostolidis
DSDaniel Schwarz
Daniel Schwarz
AXAnnie Xia
Annie Xia
MWMarkus Weiler
Markus Weiler
AHAndreas Heckel
Andreas Heckel
PBPhilipp Bäumer
Philipp Bäumer
To investigate in vivo morphological and functional correlates of oxaliplatin-induced peripheral neuropathy (OXA-PNP) by magnetic resonance neurography (MRN). Twenty patients (7 female, 13 male, 58.9±10.0 years) with mild to moderate OXA-PNP and 20 matched controls (8 female, 12 male, 55.7±15.6 years) were prospectively enrolled. All patients underwent a detailed neurophysiological examination prior to neuroimaging. A standardized imaging protocol at 3.0 Tesla included the lumbosacral plexus and both sciatic nerves and their branches using T2-weighted fat-saturated sequences and diffusion tensor imaging. Quantitative assessment included volumetry of the dorsal root ganglia (DRG), sciatic nerve normalized T2 (nT2) signal and caliber, and fractional anisotropy (FA), mean diffusivity (MD), axial (AD) and radial diffusivity (RD). Additional qualitative evaluation of sciatic, peroneal, and tibial nerves evaluated the presence, degree, and distribution of nerve lesions. DRG hypertrophy in OXA-PNP patients (207.3±47.7mm3 vs. 153.0±47.1mm3 in controls, p = 0.001) was found as significant morphological correlate of the sensory neuronopathy. In contrast, peripheral nerves only exhibited minor morphological alterations qualitatively. Quantitatively, sciatic nerve caliber (27.3±6.7mm2 vs. 27.4±7.4mm2, p = 0.80) and nT2 signal were not significantly changed in patients (1.32±0.22 vs. 1.22±0.26, p = 0.16). AD, RD, and MD showed a non-significant decrease in patients, while FA was unchanged. OXA-PNP manifests with morphological and functional correlates that can be detected in vivo by MRN. We report hypertrophy of the DRG that stands in contrast to experimental and postmortem studies. DRG volume should be further investigated as a biomarker in other sensory peripheral neuropathies and ganglionopathies.